ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Uniqure Nv

Uniqure Nv (0EE0)

31.50
0.00
( 0.00% )
更新日時: 09:00:00

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
31.50
買値
0.00
売値
0.00
出来高
0.00
0.00 日の範囲 0.00
31.50 52 週間の範囲 31.50
時価総額
前日終値
31.50
始値
-
最終取引時間
05:43:58
財務取引量
-
VWAP
-
平均取引量 (3 か月)
12,795
発行済株式数
47,834,000
配当利回り
-
PER
-2.18
1 株当たり利益 (EPS)
-6.45
歳入
21.9M
純利益
-308.48M

Uniqure Nv について

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Amsterdam, North Holland, Nld
設立
-
Uniqure Nv is listed in the Pharmaceutical Preparations sector of the ロンドン証券取引所 with ticker 0EE0. The last closing price for Uniqure Nv was US$31.50. Over the last year, Uniqure Nv shares have traded in a share price range of US$ 31.50 to US$ 31.50.

Uniqure Nv currently has 47,834,000 shares in issue. The market capitalisation of Uniqure Nv is US$1.51 billion. Uniqure Nv has a price to earnings ratio (PE ratio) of -2.18.

0EE0 最新ニュース

uniQure Announces Pricing of its Public Offering

uniQure Announces Pricing of its Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing...

uniQure Announces Proposed Public Offering

uniQure Announces Proposed Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative...

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing...

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy LEXINGTON, Mass. and AMSTERDAM, Nov. 21...

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions...

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V...

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a...

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure...

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update ~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data...

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen ~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
10031.531.531.5235031.5DE
40031.531.531.5310731.5DE
120031.531.531.51279531.5DE
260031.531.531.5848331.5DE
520031.531.531.5890231.5DE
1560031.531.531.5328231.5DE
2600031.531.531.5207431.5DE

0EE0 - Frequently Asked Questions (FAQ)

What is the current Uniqure Nv share price?
The current share price of Uniqure Nv is US$ 31.50
How many Uniqure Nv shares are in issue?
Uniqure Nv has 47,834,000 shares in issue
What is the market cap of Uniqure Nv?
The market capitalisation of Uniqure Nv is USD 1.51B
What is the 1 year trading range for Uniqure Nv share price?
Uniqure Nv has traded in the range of US$ 31.50 to US$ 31.50 during the past year
What is the PE ratio of Uniqure Nv?
The price to earnings ratio of Uniqure Nv is -2.18
What is the cash to sales ratio of Uniqure Nv?
The cash to sales ratio of Uniqure Nv is 30.68
What is the reporting currency for Uniqure Nv?
Uniqure Nv reports financial results in USD
What is the latest annual turnover for Uniqure Nv?
The latest annual turnover of Uniqure Nv is USD 21.9M
What is the latest annual profit for Uniqure Nv?
The latest annual profit of Uniqure Nv is USD -308.48M
What is the registered address of Uniqure Nv?
The registered address for Uniqure Nv is PAASHEUVELWEG 25A, AMSTERDAM, NORTH HOLLAND, 1105 BP
What is the Uniqure Nv website address?
The website address for Uniqure Nv is www.uniqure.com
Which industry sector does Uniqure Nv operate in?
Uniqure Nv operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
BLUBlue Star Capital Plc
12.00p
(45.45%)
1.11M
NTQEnteq Technologies Plc
1.45p
(45.00%)
18.81M
TIRTiger Royalties And Investments Plc
0.17p
(36.00%)
130.56M
TRLSTrellus Health Plc
3.10p
(29.17%)
11.51M
BANKFiinu Plc
9.375p
(25.00%)
4.65M
PODPPod Point Group Holdings Plc
10.50p
(-37.46%)
5.65M
PALMPanther Metals Plc
52.50p
(-36.36%)
216.84k
NOGNostrum Oil & Gas Plc
2.51p
(-23.82%)
117.55k
PRDPredator Oil & Gas Holdings Plc
5.75p
(-22.30%)
5.09M
ADMEAdm Energy Plc
0.175p
(-22.22%)
991.32k
NTVONativo Resources Plc
0.002p
(5.26%)
721.2M
TRPTower Resources Plc
0.0315p
(1.61%)
411.34M
PREMPremier African Minerals Limited
0.027p
(-3.57%)
400.53M
SYMESupply@me Capital Plc
0.0035p
(1.45%)
341.07M
TYMTertiary Minerals Plc
0.075p
(7.14%)
240.74M

最近閲覧した銘柄

Delayed Upgrade Clock